Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Utah Medical Products, Inc.NASDAQ: UTMD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $154K fell 0.6% year over year, ahead of the -5.0% change in trailing-twelve-month research & development. Sequentially, it fell 27.4% from the prior quarter. Over 3 fiscal years it compounded at +10.7% a year.
Context
- Research & development amounted to 1.7% of revenue in FY2025, down 0.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -0.6% holds above the trailing-twelve-month pace of -5.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 668K USD
- Year-over-year change
- -17.8%
- 4-year CAGR
- +6.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 668K | -17.8% |
| FY2024 | 2024-12-31 | 813K | +45.2% |
| FY2023 | 2023-12-31 | 560K | +13.6% |
| FY2022 | 2022-12-31 | 493K | -6.3% |
| FY2021 | 2021-12-31 | 526K | — |
Research & Development vs competitors
How UTMD compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.0% is the 7th highest of 10, against a peer median of +17.3%.
- Research & development amounts to 1.8% of revenue for UTMD, versus a peer median of 34.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $102.32M USD | +17.6% | -19.3% | 218.2% | |
| LTM Mar 2026 | $85.68M USD | +76.6% | +218.7% | 13864.6% | |
| LTM Mar 2026 | $46.23M USD | +68.7% | +5.5% | 40.9% | |
| LTM Mar 2026 | €42.56M EUR | +17.3% | +39.2% | 260.8% | |
| LTM Mar 2026 | $21.52M USD | +58.7% | -13.4% | 28.2% | |
| LTM Mar 2026 | $21.15M USD | -1.0% | +12.6% | 112.1% | |
| LTM Mar 2026 | $6.33M USD | -47.4% | -11.0% | 4.2% | |
| LTM Mar 2026 | $4.59M USD | -6.3% | -4.0% | 10.6% | |
| LTM Mar 2026 | $4.57M USD | -56.9% | -5.0% | 4.0% | |
| LTM Mar 2026 | $668K USD | -5.0% | +10.7% | 1.8% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UTMD) | — | +17.3% | -4.0% | 34.5% | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.05M | 52.28M | 50.22M | 40.9M | 38.52M |
| Cost of Revenue | 18.14M | 20.09M | 20.19M | 16.76M | 18.65M |
| Gross Profit | 30.92M | 32.2M | 30.04M | 24.14M | 19.88M |
| Gross Margin | 63.0% | 61.6% | 59.8% | 59.0% | 51.6% |
| Research & Development | 526K | 493K | 560K | 813K | 668K |
| Selling, General & Admin | 11.51M | 11.91M | 12.7M | 5.57M | 7.81M |
| Operating Expenses | 12.04M | 12.41M | 13.26M | 10.55M | 8.47M |
| Depreciation & Amortization | 7.28M | 7.08M | 6.37M | 2.77M | 2.95M |
| EBITDA | 26.35M | 27.74M | 24.75M | 19.57M | 17.06M |
| EBITDA Margin | 53.7% | 53.1% | 49.3% | 47.9% | 44.3% |
| Operating Income | 18.88M | 19.79M | 16.78M | 13.59M | 11.4M |
| Operating Margin | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Interest Income | 166K | 661K | 0 | 3.37M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 181K | 869K | 3.31M | 3.21M | 2.71M |
| Income Before Tax | 19.06M | 20.66M | 20.09M | 16.8M | 14.11M |
| Pre-Tax Margin | 38.9% | 39.5% | 40.0% | 41.1% | 36.6% |
| Income Tax Expense | 4.27M | 4.19M | 3.45M | 2.93M | 2.82M |
| Net Income | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
| Net Margin | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% |
| EPS (Basic) | 4.05 | 4.53 | 4.57 | 3.96 | 3.41 |
| EPS (Diluted) | 4.04 | 4.52 | 4.57 | 3.96 | 3.48 |
| Weighted Avg Shares | 3.65M | 3.64M | 3.64M | 3.5M | 3.31M |
| Weighted Avg Shares (Diluted) | 3.66M | 3.64M | 3.64M | 3.5M | 3.24M |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.